Jiro Akimoto

Prof. Dr. Jiro Akimoto

Department of Neurosurgery, Tokyo Medical University, Tokyo, Japan
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Neurologia medico-chirurgica
Verified
Journal Article
Open access
PDF file
Jiro AkimotoJiro Akimoto
Jiro Akimoto
Photodynamic therapy (PDT) using talaporfin sodium together with a semiconductor laser was approved in Japan in October 2003 as a less invasive therapy for early-stage lung cancer. The author believes that the principle of PDT would be applicable for controlling the invading front of malignant brain tumors and verified its efficacy through experiments using glioma cell lines and glioma xenograft models. An investigator-initiated clinical study was jointly conducted with Tokyo Women’s Medical University with the support of the Japan Medical Association. Patient enrollment was started in May 2009 and a total of 27 patients were enrolled by March 2012. Of 22 patients included in efficacy analysis, 13 patients with newly diagnosed glioblastoma showed progression-free survival of 12 months, progression-free survival at the site of laser irradiation of 20 months, 1-year survival of 100%, and overall survival of 24.8 months. In addition, the safety analysis of the 27 patients showed that adverse events directly related to PDT were mild. PDT was approved in Japan for health insurance coverage as a new intraoperative therapy with the indication for malignant brain tumors in September 2013. Currently, the post-marketing investigation in the accumulated patients has been conducted, and the preparation of guidelines, holding training courses, and dissemination of information on the safe implementation of PDT using web sites and videos, have been promoted. PDT is expected to be a breakthrough for the treatment of malignant glioma as a tumor cell-selective less invasive therapy for the infiltrated functional brain area.

1 June 2012 in Photodiagnosis and Photodynamic Therapy
Verified
Journal Article
Closed access
Jiro AkimotoJiro Akimoto
Jiro Akimoto
JHJo Haraoka
Jo Haraoka
KAKatsuo Aizawa
Katsuo Aizawa

21 March 2019 in Frontiers in Surgery
Verified
Journal Article
Open access
PDF file
Jiro AkimotoJiro Akimoto
Jiro Akimoto
SFShinjiro Fukami
Shinjiro Fukami
MIMegumi Ichikawa
Megumi Ichikawa
AMAwad Mohamed
Awad Mohamed
MKMichihiro Kohno
Michihiro Kohno
Objective: The aim of this study was to demonstrate the clinical feasibility of intraoperative photodiagnosis (PD) of malignant brain tumor using talaporfin sodium (TPS), which is an agent used in photodynamic therapy (PDT) for cancers. Methods: Forty-seven patients diagnosed with malignant gliomas by preoperative imaging (42 patients with gliomas and 5 patients with other brain tumors) received an intravenous injection of TPS at 40 mg/m2 24 h before resection. During surgery, these patients were irradiated with diode laser light at 664 nm, and tumor fluorescence was observed. The fluorescence intensity was visually rated on a 3-point rating scale [strong fluorescence, weak fluorescence and no fluorescence]. TPS concentrations in 124 samples from 47 cases were measured by HPLC (High performance liquid chromatography). Results: The fluorescence intensity was confirmed to be weak in all patients with Grade II gliomas and strong in almost all patients with Grade III or IV gliomas, reflecting the histological grade of malignancy. In patients with non-glioma brain tumors except for 1 patient with a metastatic brain tumor, the fluorescence intensity was strong. The mean TPS concentration in tissues was 1.62 μg/g for strong fluorescence areas, 0.67 μg/g for weak fluorescence areas and 0.19 μg/g for no fluorescence areas. Conclusions: Establishment of an appropriate fluorescence observation system enabled fluorescence-guided resection of malignant brain tumors using TPS, and the fluorescence intensity of tumors correlated with the TPS concentrations in tissues. These results suggest that TPS is a useful photosensitizer for both intraoperative fluorescence diagnosis and photodynamic therapy.

22 January 2016 in BMC Cancer
Verified
Journal Article
Open access
PDF file
Jiro AkimotoJiro Akimoto
Jiro Akimoto
HFHirokazu Fukuhara
Hirokazu Fukuhara
TSTomohiro Suda
Tomohiro Suda
KNKenta Nagai
Kenta Nagai
MIMegumi Ichikawa
Megumi Ichikawa
TNToshitaka Nagao
Toshitaka Nagao
A neuroendocrine tumor (NET) can develop anywhere in the body, but is mainly found in the pancreas, gastrointestinal tract, and lungs. This report is a retrospective study of the clinicopathological features of NET patients with brain metastasis whose tissue diagnosis was made at our hospital. Patients with brain metastasis evidenced by clinical records and images were accumulated among 302 patients in whom tissue diagnosis of NETs was made at our hospital between 2008 and 2013. In the patients, the primary lesion, pathological classification, pattern of metastasis, details of treatment, and outcomes were analyzed. Brain metastasis was observed in 31 patients (10.3 %). The primary lesion was in the lungs in 26 patients (83.9 %), and the mammary glands, esophagus, and uterus in 1 patient each. Primary lesions were unknown in 2 patients, including 1 patient in whom NETs were detected in the lymph nodes alone. Pathological classification of the primary lesion was NET Grade 2 (Ki-67: 3 to 20 %) in 3 patients and neuroendocrine carcinoma (NEC, Ki-67: ≥21 %) in 26 patients. The median period from onset of the primary lesion up to diagnosis of brain metastasis was 12.8 months, and the brain lesion preceded brain metastasis in 6 patients. Ten patients had a single metastasis whereas 21 patients had multiple metastases, but no characteristics were observed in their images. Brain metastasis was extirpated in 10 patients. Stereotactic radiotherapy alone was administered in 6 patients, and brain metastasis was favorably controlled in most of the patients with coadministration of cranial irradiation as appropriate. The median survival period from diagnosis of brain metastasis was 8.1 months, and the major cause of death was aggravation of the primary lesion or metastatic lesions in other organs. Most of NET patients with brain metastasis showed the primary lesion of NEC in the lungs, and they had multiple metastases to the liver, lymph nodes, bones, and so forth at the time of diagnosis of brain metastasis. The guidelines for accurate diagnosis and treatment of NETs should be immediately established based on further analyses of NET patients with brain metastasis.

5 September 2019 in Brain Tumor Pathology
Verified
Journal Article
Closed access
PDF file
Jiro AkimotoJiro Akimoto
Jiro Akimoto
SFShinjiro Fukami
Shinjiro Fukami
TSTomohiro Suda
Tomohiro Suda
MIMegumi Ichikawa
Megumi Ichikawa
RHRei Haraoka
Rei Haraoka
MKMasahiko Kuroda
Masahiko Kuroda

1 March 2019 in Photodiagnosis and Photodynamic Therapy
Verified
Journal Article
Closed access
MIMegumi Ichikawa
Megumi Ichikawa
Jiro AkimotoJiro Akimoto
Jiro Akimoto
YMYuichi Miki
Yuichi Miki
JMJun Maeda
Jun Maeda
TTTsutomu Takahashi
Tsutomu Takahashi
MKMichihiro Kohno
Michihiro Kohno